I really like ACUR & its potential as a biotech/pharma company... But watching its stock recently does worry me. In the recent earnings report they did mention some key catalysts occurring in this 3rd quarter yet, which could drive this stock back up again... So I'd be a careful buyer on big dips
The underlying problems with this stock is that ACUR management really does not know how to market Nexafed. It would probably be better off if it sought a major partner J&J to help market the product under the Sudafed product line. PFE is also dragging its feet on the marketing of Oxecta.. The stock has the potential to go to at least $8 easy but only with the proper marketing paths for its products. The company need a partner to market Nexafed.
This is basically a $10 or better which trades at $2 because the marketing of its products.
I have posted previously on the seemingly anemic Nexafed rollout. Agree that this is part of the issue . They have started without established distribution channel into a very crowded market. That said , would we as investors want them to be more aggressive I.e discounting to the chains, natiowide pop or media user advertising, etc if it meant considerable dilution and financial risk? On the hand longterm value is enhanced sans a partner IF they can gradually penetrate this market. Oxecta revenues are lagely now at the whim of PFE......IMO of course.
Bottomline, good time to accumulate into the weakness from Care & Claudius selling. They look to finance drug development, not marketing programs. So they are always faced with " promising" opportunities elsewhere.
just look at ACUR form 4. There should be no question whats happening to the stock, Care Cap and Claudius are selling like crazy. If you compare the chart to the sell dates, you'll see that both these funds are responsible for major downward spikes as well as the overall down trend due to pretty consistent pressure.
On July 1st ACUR spiked on the news the oxecta news. On July 1st Care Capital sold 581,082 shares, roughly the equivilent of an average trading day's volume.
If you examine the form 4 for ACUR you will understand whats happening. The question is: when will they stop selling? They could very well sell the thing down to 1.50 or lower. However, when the selling stops, ACUR will fly . Def worth scaling into a position at these levels, just remember to sell on spikes, because they will.
yes best for swing trading just bought 20K shares at 1.89 anytime under 1.90 I buy set your sell for 2.49 this one goes in waves. They have a great needed product just need to sell company or partner with J&J